Related Experiment Video

Updated: Mar 28, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma

Elias Orouji1,2, Azadeh Orouji2, Timo Gaiser3

  • 1Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

International Journal of Cancer
|December 20, 2015
PubMed

Insights

For NRAS/BRAF wild-type melanoma, gene copy gains in MAP2K1 (MEK1) and MAPK3 (ERK1) activate the MAPK pathway. Analyzing pMEK and pERK expression can identify patients for MEK and ERK inhibitor therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Recent advances target BRAF, NRAS, and cKit mutations in melanoma.
  • Limited therapeutic options exist for NRAS/BRAF wild-type melanoma.
  • The MAPK signaling pathway is crucial in melanoma progression.

Purpose of the Study:

  • Investigate gene copy number variations in the MAPK pathway in different melanoma subgroups.
  • Identify potential therapeutic targets for NRAS/BRAF wild-type melanoma.
  • Correlate gene dosage with pathway activation and clinical outcomes.

Main Methods:

  • Analysis of gene copy numbers for MAPK pathway members across melanoma subgroups.
  • Assessment of gene dosage effects on pathway activation.
  • Evaluation of pMEK and pERK expression as biomarkers.

Main Results:

  • NRAS/BRAF wild-type melanoma metastases show significant gains in MAP2K1 (MEK1) and MAPK3 (ERK1) gene loci.
  • Increased gene copies correlate with MAPK pathway activation via a gene-dosage effect.
  • pMEK and pERK expression levels can be indicative of pathway activation.

Conclusions:

  • Gene copy number alterations in the MAPK pathway are a feature of specific melanoma subtypes.
  • Targeted therapies with MEK and ERK inhibitors may benefit NRAS/BRAF wild-type melanoma patients.
  • pMEK and pERK expression analysis can guide treatment decisions for these patients.
Keywords:
BRAFERKMEKNRASmelanoma

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.7K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.5K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K